AR088258A1 - Inhibidores de la pde10 de azetidina 1,3-sustituida - Google Patents
Inhibidores de la pde10 de azetidina 1,3-sustituidaInfo
- Publication number
- AR088258A1 AR088258A1 ARP120103729A ARP120103729A AR088258A1 AR 088258 A1 AR088258 A1 AR 088258A1 AR P120103729 A ARP120103729 A AR P120103729A AR P120103729 A ARP120103729 A AR P120103729A AR 088258 A1 AR088258 A1 AR 088258A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- groups
- alkyl
- heterocycle
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544065P | 2011-10-06 | 2011-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088258A1 true AR088258A1 (es) | 2014-05-21 |
Family
ID=48044097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103729A AR088258A1 (es) | 2011-10-06 | 2012-10-05 | Inhibidores de la pde10 de azetidina 1,3-sustituida |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9365562B2 (OSRAM) |
| EP (1) | EP2763672B1 (OSRAM) |
| JP (1) | JP2014528446A (OSRAM) |
| AR (1) | AR088258A1 (OSRAM) |
| AU (1) | AU2012318874A1 (OSRAM) |
| CA (1) | CA2851082A1 (OSRAM) |
| TW (1) | TW201321369A (OSRAM) |
| WO (1) | WO2013052395A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| TW201422610A (zh) * | 2012-11-15 | 2014-06-16 | Merck Sharp & Dohme | 作爲ｐｄｅ１０抑制劑之經二級醇取代之三唑 |
| US9284302B2 (en) | 2012-11-15 | 2016-03-15 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as PDE 10 inhibitors |
| US9359348B2 (en) | 2012-11-15 | 2016-06-07 | Merck Sharp & Dohme Corp. | Cyclopropyl imidazopyridine PDE10 inhibitors |
| EP2922543B1 (en) | 2012-11-20 | 2017-05-24 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as pde10 inhibitors |
| WO2014081619A1 (en) | 2012-11-20 | 2014-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| ES2480341B1 (es) * | 2013-01-24 | 2015-01-22 | Palobiofarma S.L | Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10) |
| HK1213251A1 (zh) | 2013-03-14 | 2016-06-30 | Novartis Ag | 作为突变idh抑制剂的3-嘧啶-4-基-恶唑烷-2-酮化合物 |
| FR3040057A1 (fr) * | 2015-08-13 | 2017-02-17 | Inventiva | Composes de type azetidine carboxylique |
| US10583269B2 (en) | 2016-06-01 | 2020-03-10 | Becton, Dickinson And Company | Magnetized catheters, devices, uses and methods of using magnetized catheters |
| EP3676264A1 (en) * | 2017-08-28 | 2020-07-08 | Acurastem Inc. | Pikfyve kinase inhibitors |
| CN120365272A (zh) | 2018-10-05 | 2025-07-25 | 安娜普尔纳生物股份有限公司 | 用于治疗与apj受体活性有关的疾病的化合物和组合物 |
| US20230135152A1 (en) * | 2020-02-11 | 2023-05-04 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
| WO2025049402A1 (en) * | 2023-08-28 | 2025-03-06 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0968206T3 (da) * | 1997-02-19 | 2007-03-26 | Berlex Inc | N-heterocykliske derivater som NOS-inhibitorer |
| EP1499598A1 (en) * | 2002-04-18 | 2005-01-26 | Ucb, S.A. | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
| HRP20050696B1 (en) * | 2003-01-14 | 2008-10-31 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| DE102008020113A1 (de) | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| JP2008534481A (ja) * | 2005-03-23 | 2008-08-28 | アストラゼネカ アクチボラグ | インスリン様増殖因子−１受容体活性の阻害剤としての２−アゼチジニル−４−（１ｈ−ピラゾール−３−イルアミノ）ピリミジン |
| EP1877385A1 (en) * | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
| CA2654792A1 (en) * | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| DE102006050513A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| UA97506C2 (xx) * | 2006-12-28 | 2012-02-27 | Эбботт Лаборетриз | Інгібітори полі(adp-рибозо)полімерази$ингибиторы поли(adp-рибозо)полимеразы |
| CN101896472A (zh) | 2007-12-13 | 2010-11-24 | 锡耶纳生物技术股份公司 | Hedgehog途径拮抗剂及其治疗应用 |
| EP2276750A2 (en) * | 2008-03-27 | 2011-01-26 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| MX2012013128A (es) * | 2010-05-13 | 2013-03-20 | Amgen Inc | Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10. |
| US8785467B2 (en) | 2010-09-30 | 2014-07-22 | Merck Sharp & Dohme Corp. | Alkoxy pyrimidine PDE10 inhibitors |
| MY157301A (en) | 2011-08-25 | 2016-05-31 | Merck Sharp & Dohme | Pyrimidine pde10 inhibitors |
-
2012
- 2012-10-01 JP JP2014534619A patent/JP2014528446A/ja not_active Withdrawn
- 2012-10-01 CA CA2851082A patent/CA2851082A1/en not_active Abandoned
- 2012-10-01 EP EP12838133.2A patent/EP2763672B1/en active Active
- 2012-10-01 US US14/349,041 patent/US9365562B2/en active Active
- 2012-10-01 AU AU2012318874A patent/AU2012318874A1/en not_active Abandoned
- 2012-10-01 WO PCT/US2012/058220 patent/WO2013052395A1/en not_active Ceased
- 2012-10-05 TW TW101137034A patent/TW201321369A/zh unknown
- 2012-10-05 AR ARP120103729A patent/AR088258A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2763672B1 (en) | 2016-08-10 |
| US20140256708A1 (en) | 2014-09-11 |
| US9365562B2 (en) | 2016-06-14 |
| EP2763672A4 (en) | 2015-03-04 |
| CA2851082A1 (en) | 2013-04-11 |
| EP2763672A1 (en) | 2014-08-13 |
| JP2014528446A (ja) | 2014-10-27 |
| AU2012318874A1 (en) | 2014-05-15 |
| TW201321369A (zh) | 2013-06-01 |
| WO2013052395A1 (en) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088258A1 (es) | Inhibidores de la pde10 de azetidina 1,3-sustituida | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR087628A1 (es) | Inhibidores de pde10 de pirimidina | |
| AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
| AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| AR090203A1 (es) | Compuestos heterobiciclicos como inhibidores de pde10 | |
| AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR078153A1 (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR078321A1 (es) | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR115015A1 (es) | Derivados de azaespiro piperazina | |
| CR20190261A (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR088320A1 (es) | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt | |
| BR112017019685A2 (pt) | composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condição | |
| AR095267A1 (es) | Compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| AR085711A1 (es) | Compuesto de heteroaril oximetilen arilo sustituido, composicion farmaceutica y combinacion que lo comprenden y su uso para la fabricacion de un medicamento para el tratamiento de una enfermedad autoinmune, cancer, una enfermedad inflamatoria y/o un trastorno alergico y una enfermedad asociada con la activacion inapropiada de las celulas cebadas | |
| AR093128A1 (es) | Inhibidores de la syk | |
| AR097772A1 (es) | Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediado por actividad quinurenina-3-monooxigenasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |